The currently approved indications for Sindilizumab Injection include relapsed or refractory classical Hodgkin’s lymphoma, non-squamous non-small cell lung cancer, advanced squamous non-small cell lung cancer, and unresectable or metastatic hepatocellular carcinoma.
Sindilizumab injection is a kind of immune checkpoint inhibitor antitumor drug, which is mainly used in anticancer treatment by restoring the function of human immune system, so that the immune cells with killing power can kill cancer cells.
At present, several clinical studies have confirmed that patients with advanced relapsed refractory Hodgkin’s lymphoma, or advanced squamous cell carcinoma of the lung, or advanced non-small cell lung cancer without gene mutation, or advanced hepatocellular carcinoma, the use of Sindilizumab can lead to the shrinkage of the tumor or stable non-development of the tumor, and the reduction of the patient’s symptoms, and it can prolong the survival time of the patients with advanced stage.
After the use of Sindilizumab Injection, side effects such as rash, liver toxicity, pneumonia and diarrhea may occur, and professional medical guidance is required for the treatment of similar symptoms.